Bevacizumab vs Dacarbazine in Metastatic Melanoma

NCT01705392 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

2

Enrollment

OTHER

Sponsor class

Stopped Lack of financing of the study drug. Not sufficient financial support.

Conditions

Metastatic Malignant Melanoma
Unresectable Malignant Melanoma

Interventions

DRUG: Bevacizumab
DRUG: Propranolol
DRUG: Enalapril
DRUG: Dacarbazine

Sponsor

Haukeland University Hospital

Collaborators

[object Object]
[object Object]